Background. Although tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a predictor of adherence and pre-exposure prophylaxis efficacy, its utility in human immunodeficiency virus (HIV) treatment remains unknown.
The main driver of antiretroviral therapy (ART) exposure and human immunodeficiency virus (HIV)-related outcomes is medication adherence [1] [2] [3] . Optimal adherence is critical to achieve and sustain viral suppression in people living with HIV (PLWH) [4, 5] . Despite this, we currently lack a gold standard measure of ART adherence and exposure that can be used in clinical practice [6, 7] . In particular, measures that distinguish between viremia due to suboptimal adherence vs inadequate viral response (eg, persistent viremia due to drug resistance or low cumulative drug exposure despite high adherence) are currently unavailable.
Tenofovir diphosphate (TFV-DP), arising from tenofovir disoproxil fumarate (TDF)-and tenofovir alafenamide (TAF)-based regimens [8, 9] , is the phosphorylated anabolite of tenofovir (TFV) and exerts its pharmacodynamic effect in HIV-infected cells. This anabolite is also abundant in red blood cells [10, 11] and dried blood spots (DBS) [11] [12] [13] , where it exhibits unique pharmacology, with a long half-life of 17 days and a 25-fold accumulation from the first dose to steady state [11] . These distinctive pharmacologic characteristics have been leveraged to develop an adherence gradient in HIVnegative persons [11, 14] that is predictive of HIV pre-exposure prophylaxis (PrEP) efficacy [15] [16] [17] and correlates with other adherence measures in HIV [18, 19] . However, this biomarker as an indicator of viral suppression and drug exposure in PLWH on ART has not been evaluated. This is a significant gap in knowledge given the >20 million PLWH receiving ART worldwide [20] (many of whom are on TFV-based regimens in the United States [>85%] [21] and around the world [22] ) and the proportion in whom viral suppression has not been achieved [23] .
We therefore investigated the association of TFV-DP with viral suppression in a clinical cohort of PLWH being treated with TDF-based ART.
METHODS

Study Design and Participants
Study participants were recruited at the University of Colorado Hospital Infectious Diseases Group Practice in Aurora, Colorado. Inclusion criteria required that participants were 18 years or older, taking a TDF-based regimen (for any duration of time), and planned to have blood drawn for routine HIV viral load (VL) analysis at every study visit as part of their routine medical care. There were no restrictions on the co-existence of comorbidities for enrollment. Prospective enrollment of participants occurred on a first-come and firstserved basis during their clinic visit. After obtaining informed consent, 4-6 mL of whole blood were collected in 1 ethylenediaminetetraacetic acid tube from peripheral venipuncture during the participant's clinical blood draw. A maximum of 3 study visits (ie, 3 blood samples) were obtained within a 48-week period of time. Participants were compensated $10.00 for every study visit, for a maximum of $30.00. Study visits were dependent on participants' scheduled follow-up with their provider, but were required to be at least 2 weeks apart to allow for 1 half-life of TFV-DP in DBS [11] . Study enrollment was initiated in June 2014, and follow-up for the last enrolled participant concluded in July 2017. Throughout this period, the rate of viral suppression within the University of Colorado Hospital Infectious Diseases Group Practice ranged from 84-90%, and TDF continued to be the most-prescribed nucleoside analogue, as the clinic's prescribing practices did not automatically switch to TAF after its 2015 approval. The study was approved by the Colorado Multiple Institutional Review Board (COMIRB #13-2104) and registered with clinicaltrials. gov (NCT02012621).
Our primary outcome, HIV VL, was evaluated at all study visits to inform patient care, and DBS samples were collected to coincide with these available measurements. Through August 2016, DBS at each study visit were consecutively assayed, regardless of HIV VL, as originally planned. At this point, logistical and practical constraints limited our analytical capacity and a reduced DBS assay strategy was implemented. For the remainder of the study, DBS assays were performed for all study visits for participants with a detectable HIV VL measurement at 1 or more visits, while DBS assays were discontinued for participants with suppressed HIV VL at all observed visits. This outcome-dependent sampling strategy is similar to a case (viremic) control (suppressed) study design extended to a longitudinal setting. Under outcome-dependent sampling, statistical power is maintained by enriching the sample for the reasonably rare outcome (<20% of study visits) [24] .
Quantification of Tenofovir Diphosphate in Dried Blood Spots
For the DBS preparation, 25 mcl of whole blood were pipetted 5 times into a Whatman 903 Protein Saver card, as previously described [11, 12] . These cards were allowed to dry at room temperature for at least 2 hrs (and up to overnight), after which they were stored in plastic bags with humidity indicators at -80 o C until analysis [11, 12, 14] . TFV-DP was quantified from a 3 mm punch using liquid chromatography/tandem mass spectrometry, as previously validated [12] .
Self-reported Adherence Assessment
At each study visit, participants were asked about their 3-month adherence to their current ART regimen using a visual analog scale ranging from 0% to 100% adherence [25, 26] . Briefly, study personnel asked the participant to mark on a horizontal line that ranged from 0% to 100%, with predefined intervals every 10%, their best estimate of adherence in that period. Since study visits were dependent on scheduling for clinical care, overlap on the time period assessing self-reported adherence was possible.
HIV Viral Load Analysis
Quantitative HIV-1 VL analysis was performed using the Roche cobas 6800 HIV test (linear range 20 to 10 7 copies/mL) at the University of Colorado Hospital clinical laboratory, which is certified under the Clinical Laboratory Improvement Amendment of 1988.
Statistical Analysis
TFV-DP concentrations were log-transformed for analysis to address right skew, and results were back-transformed to the geometric mean for ease of interpretation in units of drug concentration (fmol/punch) [27] . Baseline TFV-DP concentrations were compared using t-tests or analyses of variance, or their non-parametric counterparts, as appropriate. In order to analyze all available visit data, drug concentrations below the limit of quantification were imputed to 12.5 fmol/punch, which is between 0 and the lower limit of quantification of the assay [12] . TFV-DP concentrations were classified into 5 categories based on previous studies in HIV-uninfected individuals [14] . While the adherence:concentration benchmarks in PLWH have not been determined, this classification was considered to be a reasonable starting point for this analysis. To accommodate repeated measures over time, generalized estimating equations with a logit link were used to estimate the odds ratios (OR) of viral suppression (<20 copies/mL), comparing each TFV-DP category to the reference category of <350 fmol/punch. An adjusted OR (aOR) was obtained by including covariates for age, gender, race, body mass index (BMI), estimated glomerular filtration rate (using Modification of Diet in Renal Disease equation), CD4 + T-cell count, ART class, and duration of ART in the model. Adjustment variables were selected a priori based on previous findings on the pharmacology of TFV in plasma [28, 29] and TFV-DP in peripheral blood mononuclear cells (PBMCs) [30] and DBS [14] . Current ART therapy duration was also categorized, with the highest category being >6 months, when TFV-DP in DBS would be at a steady state [11, 14] . A separate, generalized estimating equation model of viral suppression considered the association of suppression with the 3-month, self-reported adherence categories: <28.5% (reference category), 28.5% to <50%, 50% to 84%, 85% to 99%, and 100%, aiming to mirror the TFV-DP categories and also based on previous studies in HIV-uninfected volunteers. These models of viral suppression, utilizing either TFV-DP in DBS or 3-month self-reported adherence, were compared using the quasilikelihood under the independence model criterion [31] .
To address the outcome-dependent sampling and confirm the strength of our findings, we performed a sensitivity analysis limiting data to those collected during the initial phase of the study (ie, before August 2016, when the DBS assay strategy was modified).
RESULTS
Study Population
A total of 807 participants were enrolled, 619 (77%) of whom were suppressed to <20 copies/mL at enrollment, contributing 1939 person-visits and 1936 DBS samples, with 444 completing all 3 visits (275 suppressed at all visits), 244 completing 2 visits (189 suppressed at both visits), and 119 completing only 1 visit (98 suppressed). The demographic characteristics of the participants for whom DBS were analyzed for drug concentrations (n = 532) are presented in Table 1 , and comparisons with the participants for whom drug concentrations in DBS were not quantified (n = 272) are presented in Supplementary Table 1 , without major differences observed between these 2 groups.
Among the 532 participants for whom DBS were analyzed (n = 1199 person-visits), the median time between visits was 16 (range 2, 48) weeks. Across person-visits, 839 (70%) samples had an HIV VL <20 copies/mL, 213 (18%) had 20-200, and 147 (12%) had >200 copies/mL. The HIV VL in viremic participants upon enrollment is shown in Table 1 , and ranged from 20 to 331 000 copies/mL.
Tenofovir Diphosphate Concentrations in Dried Blood Spots
TFV-DP was quantified in DBS from 1199 person-visits (derived from 532 participants) and included in the drug concentration analysis; 11 samples (<1%) were below the limit of quantification. TFV-DP concentrations were available for 521 participants at enrollment (7 samples had no paired HIV VL and 4 samples had missing drug concentrations). The baseline demographic characteristics of these 521 participants are shown in Table 1 . The geometric mean concentration of TFV-DP in all participants at enrollment was 1450 fmol/punch (95% confidence interval [CI] 1357-1548), with higher overall concentrations in the suppressed (1728, 95% CI 1601-1865) vs. viremic participants (1021, 95% CI 917-1138; P < .0001).
The TFV-DP concentrations, according to participant characteristics and viral suppression status at enrollment, are shown in Table 2 In both viremic and suppressed participants, a longer current ART duration upon enrollment was associated with higher TFV-DP concentrations (Table 2) . Similarly, drug concentrations increased significantly with higher 3-month, self-reported adherence in both groups, as shown in Table 2 . TFV-DP concentrations in viremic and suppressed participants who reported 100% adherence were 1766 (95% CI 1313-2375) and 1863 (95% CI 1726-2010) fmol/punch, respectively.
After adjusting for age, race, gender, BMI, CD4 + T-cell count, estimated glomerular filtration rate, ART class, duration of therapy, and self-reported adherence in the virologically-suppressed group, male participants had 13% (95% CI -24--0.8; P = .037) lower TFV-DP concentrations compared to women (Supplementary Table 2 ). Similarly, Whites and Hispanics had 15% (95% CI 0.4-31; P = .044) and 20% (95% CI 2-41; P = .024) higher TFV-DP concentrations vs Blacks, respectively. Participants with BMIs >30 Kg/m 2 had 47% (95% CI 31-59; P < .0001) lower drug concentrations compared to those with BMIs <18.5 Kg/m 2 (Supplementary Table 2 ).
Self-reported Adherence
A total of 482 participants (337 suppressed, 145 viremic) had data available for 3-month, self-reported adherence at enrollment, with a median adherence of 99% (interquartile range [IQR] 90-100) and 90% (IQR 80-100) adherence in suppressed and viremic participants, respectively (Table 1) . Median adherence was similar in women (100%, IQR 90-100) vs men (98%, IQR 90-100; P = .38) and in Blacks (95%, IQR 90-100) compared to Whites (98%, IQR 90-100; P = .18) and Hispanics (98%, IQR 90-100; P = .65). Adherence in participants taking an NNRTIbased regimen (100%, IQR 94-100) was higher compared to participants taking a boosted protease inhibitor-based (96%, IQR 85-100; P = .01), an integrase-based (97%, IQR 90-100; P = .07), or a multiclass-based (95%, IQR 87-100; P = .006) regimen. Participants taking a pharmacologic booster (95%, IQR 85-100) had lower adherence compared to those who were not (99%, IQR 93-100; P < .0001).
Association of Tenofovir Diphosphate in Dried Blood Spots With Viral Suppression
The distribution of all person-visits by TFV-DP concentration category and 3-month self-reported adherence are shown in Tables 3 and 4 , respectively. The aORs of viral suppression, based on the TFV-DP concentration categories, are shown in Table 3 and Figure 1 . The highest estimated aOR for suppression was 73.5 (95% CI 25.7-210.5; P < .0001) for TFV-DP concentrations ≥1850 fmol/punch vs <350 fmol/punch. The estimated aOR of viral suppression, based on self-reported adherence, are shown in Table 4 and Supplementary Figure 1 , estimated as 8.5 (95% CI 2.3-30.9; P = .0012) for 100% vs. <28.5% adherence and 8.6 (95% CI 2.3-31.2; P = .011) for 85-99% vs. <28.5% adherence. The quasilikelihood under the independence model criterion for the model including TFV-DP in DBS was substantially lower vs. the model including 3-month self-reported adherence (1149 vs. 1233), indicating the TFV-DP model fit the data better. 
Sensitivity Analysis
In the subset of participants for whom DBS were consecutively analyzed prior to the modification of the assay strategy, the aOR for viral suppression was 81.3 (95% CI 17.9-368.6; P < .0001) for a TFV-DP concentration of ≥1850 fmol/punch, compared to <350 fmol/punch (Supplementary Table 3 ).
DISCUSSION
In this study, we found that TFV-DP in DBS was strongly associated with virologic suppression to <20 copies/mL, and that this association was stronger than self-reported adherence. This association increased with higher TFV-DP concentrations, and remained significant after covariate adjustment, including ART class and therapy duration. In comparison to the extensive body of literature that has demonstrated the utility of TFV-DP in DBS as a predictor of PrEP efficacy [15] [16] [17] , this study provides new additional insights about its association with viral suppression and potential applications in HIV infection. Our findings suggest PLWH may have higher TFV-DP concentrations in DBS than HIV-uninfected volunteers [11, 14] and that TFV-DP concentrations in DBS are likely to be influenced by individual characteristics unique to this population, such as the use of concomitant medications or additional comorbidities. For example, while TFV-DP concentrations were lower in virologically-suppressed Black PLWH compared to other races, they were still higher than previous estimates in HIVuninfected Blacks [14] , despite similar self-reported adherence. This suggests that ART adherence may not be the main driver of these differences; they could be influenced by drug-drug interactions, chronic inflammation [32] , and/or unique pharmacogenetics/biology in PLWH. Similarly, BMI was also associated with TFV-DP concentrations in participants with viral suppression, even after adjusting for race and gender, suggesting that TFV and TFV-DP exposure could be influenced by body habitus. This is consistent with previous observations, where low BMI was associated with high plasma TFV [28, 29, 33] . We also observed associations between TFV-DP exposure and ART regimen. For instance, virally-suppressed participants taking an NNRTI-based regimen (mainly efavirenz) had an average TFV-DP concentration of 1563 fmol/punch vs. 1888 fmol/ punch for suppressed participants taking a regimen including a pharmacologic booster. These findings are consistent with previous observations, where high levels of TFV in plasma [28] [29] [30] [34] [35] [36] [37] [38] , TFV-DP in PBMCs [30, 39] and TFV in hair [40] were observed in patients taking pharmacologic boosters. Among the possible explanations are that ritonavir and cobicistat may increase TDF (and consequently TFV) uptake into the systemic circulation by altering the activity of P-glycoprotein (ie, via reduction of TDF efflux) and by inhibiting esterase cleavage of TDF at the luminal gut level [41] or that pharmacologic boosters may slow the renal clearance of TFV due to an inhibition of efflux transporters, such as the multidrug resistance proteins 4 and 2 in the renal proximal tubule [38, 42] . Collectively, these findings suggest TFV-DP in DBS may have a different pharmacokinetic profile in PLWH compared to HIV-uninfected adults, and that the known adherence benchmarks in the HIVuninfected population are unlikely to apply directly to PLWH. A directly-observed dosing study in PLWH would help establish expected TFV-DP benchmarks in this population and help parse sources of TFV-DP variability.
Along with the association of TFV-DP with viral suppression in PLWH, potential applications in clinical practice should be discussed. These include the possibility of utilizing TFV-DP in DBS as a tool to inform ART adherence and exposure beyond HIV VL, in particular if this biomarker is developed as a pointof-care test. While HIV VL has been traditionally used as a surrogate for ART adherence, it cannot provide information about drug exposure or pharmacologic forgiveness. For example, HIV The italicized values are meant to show statistical significance.
Abbreviations: aOR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval; HIV VL, human immunodeficiency virus viral load; IQR, interquartile range; OR, odds ratio; TFV-DP, tenofovir diphosphate; a Adjusted for age, gender, race, body mass index, estimated glomerular filtration rate, CD4 + T-cell count, ART class, and duration of ART.
VL cannot detect low drug exposure in suppressed individuals, which could trigger an early intervention to improve adherence and prevent viral rebound. In this context, TFV-DP in DBS could serve as a true predictor of viral rebound, in particular if a low concentration is associated with future viremia (despite viral suppression at the time of analysis). Conversely, since HIV VL cannot identify high cumulative drug exposure in the presence of viremia, a high TFV-DP concentration in a patient with a persistently-elevated HIV VL could suggest drug resistance and trigger early HIV genotyping. Furthermore, given its unique pharmacology, TFV-DP in DBS could also be used as a tool to monitor and/or predict drug-related toxicity in clinical practice, as it is plausible that high accumulation could precede overt clinical toxicity or drug discontinuation (as seen in highrisk individuals taking TDF for PrEP) [43, 44] . Future research is needed to evaluate these potential applications. Our study offers several strengths, including a large sample size within a prospective clinical cohort reflective of a routine clinical practice. This provides for generalizability of our findings and sets the framework for the use of TFV-DP as a measure of cumulative adherence and exposure in clinical care. Additional strengths include the stronger association of this objective adherence biomarker in comparison with self-reported ART adherence and the range of potential applications in clinical practice. Among the limitations are that our study was observational, with adherence based on self-report and virologic suppression. In addition, our outcome-dependent sampling strategy could have strengthened our association, although our sensitivity analysis, limited to person-visits that were consecutively obtained, provided a similar, although larger, aOR. Lastly, the study was restricted to participants on TDF-based regimens. However, DBS from participants switching to TAF-based regimens during the course of the study were collected and will be analyzed in the future.
In summary, we demonstrated that TFV-DP in DBS is strongly associated with viral suppression in PLWH. In addition, TFV-DP exposure in our population was higher than that previously observed in HIV-negative volunteers, and was associated with several patient characteristics, such as race, BMI, ART class, and the use of a pharmacologic booster. Further research is needed to better understand how these individual factors contribute to the pharmacology of TFV-DP in patients on ART, including those on TDF-and TAF-based regimens. Finally, the utility of this adherence biomarker as a tool to monitor ART adherence in clinical practice should be evaluated.
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